Multiple Myeloma

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses treatment after CAR T-cell therapy in patients with myeloma.

Although many new drugs have been introduced for treating patients with hematologic malignancies, stem cell transplantation remains a vital part of the therapeutic paradigm, particularly for multiple myeloma and non-Hodgkin lymphoma.

Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses carfilzomib (Kyprolis) dosing in the treatment of patients with multiple myeloma.

A multitude of BCMA-targeted CAR T-cell therapies are currently in development, each demonstrating different efficacy and safety profiles and each with different constructs.

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco (UCSF); co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses minimal residual disease (MRD) status in multiple myeloma.

The triplet of daratumumab, lenalidomide, and dexamethasone reduced the risk of disease progression or death by 44% compared with lenalidomide plus dexamethasone in newly diagnosed patients with multiple myeloma who were not candidates for high-dose chemotherapy and autologous stem-cell transplant.

A Selinexor combination regimen induced an overall response rate of 26.2% in heavily pretreated patients with penta-refractory multiple myeloma.

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses initial results from a phase I clinical trial of bb21217, a next-generation anti-BCMA CAR T-cell therapy, in patients with multiple myeloma during the 2018 ASH Annual Meeting.

The anti-BCMA CAR T cell therapy bb21217 demonstrated an objective response rate of 83.3%, with a very good partial response or better rate of 75% in patients with heavily pretreated relapsed/refractory multiple myeloma.

Two-year maintenance therapy with ixazomib led to a 39% improvement in progression-free survival compared with placebo in patients with newly diagnosed multiple myeloma who achieved a partial response to induction treatment with a proteasome inhibitor and/or an immunomodulatory agent following autologous stem cell transplant.

Daratumumab added to bortezomib, lenalidomide, and dexamethasone induced at least a very good partial response in all patients and a stringent complete response or CR in 63% of patients at the end of consolidation therapy in the run-in phase of an open-label study of transplant-eligible patients with newly diagnosed multiple myeloma.

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Health System, discusses the importance of biology in multiple myeloma.

Ahead of the 2018 ASH Annual Meeting, multiple myeloma experts Sundar Jagannath, MBBS, selected the most pivotal abstracts in their field.

During an OncLive Peer Exchange®, a panel of experts on multiple myeloma discussed new agents and combinations that are improving the care of patients with relapsed multiple myeloma and reviewed strategies for treating these patients when they develop drug resistance.